Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.5100 (-8.05%) ($6.4400 - $6.9700) on Mon. Aug. 5, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4% (three month average) | RSI | 29 | Latest Price | $6.5100(-8.05%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.4% a day on average for past five trading days. | Weekly Trend | TGTX declines -3.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -2% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-9%) IFRA(-7%) UUP(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2% (StdDev 4%) | Hourly BBV | 0 () | Intraday Trend | -6.3% | | | |
|
1 - 5 Day Possible Target | $-3.35(-151.46%) | Resistance Level | $7.59 | 5 Day Moving Average | $7.21(-9.71%) | 10 Day Moving Average | $7.29(-10.7%) | 20 Day Moving Average | $7.59(-14.23%) | To recent high | -27.6% | To recent low | 3.8% | Market Cap | $824m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |